Minot Light Capital, an investment management firm, recently released its fourth-quarter 2024 investor letter. A copy of the ...

Fact checked by Nick Blackmer Two Alzheimer's drugs that target amlyoid plaques have been approved for months, but many hospitals are only now starting to offer these treatments. Leqembi ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine ...

The global precision diagnostics and medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, reaching US$145.53 billion in 2024 and an impressive US$246.

Toripalimab, independently developed by Junshi Biosciences, is a monoclonal antibody targeting PD-1 for the treatment of ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

In the Chinese mainland, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in ...

IFRX stock gains 8% on EC nod for Gohibic, under exceptional circumstances, to treat adult patients with COVID-19-induced ...

We recently published an article titled 10 Firms Post Impressive Gains on Tuesday. In this article, we are going to take a ...

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Proposed changes to this list are open for consultation. Learn about the consultation and how to provide your feedback. The consultation closes on March 8, 2025. Drugs included on the list for ...

BRIUMVI is a novel monoclonal ... antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated for the ...